•
Dec 31, 2022
Mink Therapeutics Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year 2022.
Key Takeaways
MiNK Therapeutics reported a net loss of $7.8 million for the fourth quarter of 2022, with a cash balance of $19.6 million at the end of the quarter.
Ended Q4 2022 with a cash balance of $19.6 million.
Cash used in operations for Q4 2022 was $4.4 million.
Net loss for Q4 2022 was $7.8 million, or $0.23 per share.
The increased funding was related to the internalization of our cGMP manufacturing of agenT-797 for clinical trial supply, which has increased our production and will result in decreased supply cost prospectively.